<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189019</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4928</org_study_id>
    <nct_id>NCT01189019</nct_id>
  </id_info>
  <brief_title>HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration</brief_title>
  <acronym>HiPED</acronym>
  <official_title>High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Fung MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pacific Eye Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are&#xD;
      collecting groups of patients who either do not or only partially respond to anti-VEGF&#xD;
      therapy. This study will evaluate the efficacy and safety of 2mg ranibizumab specifically for&#xD;
      patients with fibrovascular PEDs that have not resolved following at least 6 consecutive&#xD;
      injections of ranibizumab or bevacizumab over the previous 12 months. The investigators&#xD;
      hypothesize that the 2mg dose will be able to completely eliminate the persistent PEDS in&#xD;
      these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drug dose became unavailable&#xD;
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in visual acuity from baseline to 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Best corrected visual acuity on the ETDRS chart at 4 meters will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>BCVA on ETDRS will be compared from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>incidence and severity of ocular and non-ocular adverse events will be evaluated through 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% with &gt; 15 ETDRS letter gain from baseline through 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OCT CST from baseline through 6 and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of PED in PRN Arm</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <condition>Macular Degeneration</condition>
  <condition>Retinal Pigment Epithelial Detachment</condition>
  <arm_group>
    <arm_group_label>Group 1 - 2mg ranibizumab monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg ranibizumab monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - 2mg x 3 then PRN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>2mg intravitreal injection monthly</description>
    <arm_group_label>Group 1 - 2mg ranibizumab monthly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT</description>
    <arm_group_label>Group 2 - 2mg x 3 then PRN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  Active or recurrent neovascular age-related macular degeneration involving the fovea&#xD;
             on FA&#xD;
&#xD;
          -  Presence of persistent fibrovascular pigment epithelial detachment on OCT following a&#xD;
             minimum 6 previous treatments in previous 12 months with ranibizumab and/or&#xD;
             bevacizumab. Patients may have received more than 12 months of anti-VEGF therapy.&#xD;
&#xD;
          -  ETDRS Best Corrected Visual acuity 20/32 - 20/400&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with verteporfin, or external-beam radiation therapy, or&#xD;
             transpupillary thermotherapy, Previous subfoveal focal laser photocoagulation&#xD;
             involving the foveal center, History of vitrectomy, submacular surgery, or other&#xD;
             surgical intervention for AMD, Previous participation in any studies of&#xD;
             investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals)&#xD;
             in study eye.&#xD;
&#xD;
          -  Lesion Characteristics: Subfoveal fibrosis or atrophy in study eye, CNV in either eye&#xD;
             due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia.&#xD;
&#xD;
          -  Concurrent Ocular Conditions: Concurrent eye disease in the study eye that could&#xD;
             compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma), Any&#xD;
             concurrent intraocular condition in the study eye (e.g., diabetic retinopathy or&#xD;
             glaucoma) that, in the opinion of the investigator, could either, Require medical or&#xD;
             surgical intervention during the 12-month study period to prevent or treat visual loss&#xD;
             that might result from that condition, or If allowed to progress untreated, could&#xD;
             likely contribute to loss of at least 2 Snellen equivalent lines of best corrected&#xD;
             visual acuity over the 12-month study period, Active intraocular inflammation (grade&#xD;
             trace or above) in the study eye, or history of idiopathic or autoimmune-associated&#xD;
             uveitis in either eye&#xD;
&#xD;
          -  Current vitreous hemorrhage in the study eye&#xD;
&#xD;
          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the&#xD;
             study eye&#xD;
&#xD;
          -  Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye&#xD;
&#xD;
          -  Aphakia or absence of the posterior capsule in the study eye unless it occurred as a&#xD;
             result of YAG posterior capsulotomy in association with prior, posterior chamber&#xD;
             intraocular lens implantation.&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure 30 mmHg&#xD;
             despite treatment with anti-glaucoma medication)&#xD;
&#xD;
        Concurrent Systemic Conditions&#xD;
&#xD;
          -  Pregnancy or premenopausal women not using adequate contraception The following are&#xD;
             considered effective means of contraception: surgical sterilization; use of oral&#xD;
             contraceptives; barrier contraception with either a condom or diaphragm in conjunction&#xD;
             with spermicidal gel; an IUD; or contraceptive hormone implant or patch.&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use an investigational drug or that might affect interpretation of&#xD;
             the results of the study or render the subject at high risk for treatment&#xD;
             complications&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Inability to dilate pupils sufficient for adequate fluorescein angiography&#xD;
&#xD;
          -  Inability to comply with study or follow up procedures&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test)&#xD;
&#xD;
          -  Any other condition that the investigator believes would pose a significant hazard to&#xD;
             the subject if the investigational therapy were initiated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Fung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Eye Associates / California Pacific Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Eye Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pacificeye.com</url>
    <description>Pacific Eye Associates</description>
  </link>
  <link>
    <url>http://www.tnretina.com/tennessee/retina</url>
    <description>Tennessee Retina</description>
  </link>
  <link>
    <url>http://www.retinaky.com/</url>
    <description>Retina Associates of Kentucky</description>
  </link>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pacific Eye Associates</investigator_affiliation>
    <investigator_full_name>Anne Fung MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ranibizumab</keyword>
  <keyword>Wet macular degeneration</keyword>
  <keyword>macular degeneration</keyword>
  <keyword>PED</keyword>
  <keyword>Retinal Pigment Epithelial Detachment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Presented at medical conferences, manuscript in preparation</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

